Novartis announces completion of transactions with GSK

05/03/2015 - 5 minutes
  • Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business
  • Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics
  • Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small molecules, positioning Novartis as a preferred partner for combination agents
  • Transactions expected to immediately lift core margins and further support overall financial strength

Novartis announced in March, 2nd 2015,  that it has completed a series of transactions with GlaxoSmithKline (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture that combines the two companies’ consumer divisions, and the divestiture of the Novartis non-influenza Vaccines business to GSK. The transactions were announced in April 2014 as part of the Novartis global portfolio transformation.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!